United Therapeutics Corporation (UTHR : NASDAQ)
Common Stock
$536.40
USD
-5.30 (-0.98%)
Last updated: 2026-10-05
Follow UTHR
UTHR
United Therapeutics Corporation
WealthAwesomePerformance
1 Day
-0.98%
1 Week
+10.47%
1 Month
+10.01%
YTD
+7.99%
Key Statistics
Market Cap
$23.01B
52W High
$609.35
52W Low
$409.07
P/E Ratio
19.21
50 Day MA
$511.11
200 Day MA
$525.34
Beta
0.49
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/5/2026 | $540.41 | $547.98 | $535.53 | $536.40 | $536.40 | 798,648 |
| 10/2/2026 | $570.00 | $577.02 | $541.27 | $541.70 | $541.70 | 996,700 |
| 10/1/2026 | $557.53 | $585.79 | $556.76 | $571.38 | $571.38 | 1,691,500 |
| 9/30/2026 | $482.20 | $557.37 | $475.46 | $541.89 | $541.89 | 3,336,700 |
| 9/29/2026 | $485.54 | $487.62 | $471.34 | $481.47 | $481.47 | 439,900 |
| 9/28/2026 | $473.84 | $486.98 | $470.76 | $485.54 | $485.54 | 628,200 |
| 9/25/2026 | $474.04 | $479.97 | $470.40 | $475.45 | $475.45 | 472,400 |
| 9/24/2026 | $472.72 | $481.32 | $468.97 | $472.21 | $472.21 | 585,500 |
| 9/23/2026 | $498.82 | $500.05 | $487.73 | $489.42 | $489.42 | 433,400 |
| 9/22/2026 | $493.98 | $499.58 | $488.08 | $497.59 | $497.59 | 586,400 |
Analyst Price Targets
Based on 15 analysts covering UTHR · as of Oct 5, 2026
Wall Street analysts forecast UTHR stock price to rise 20.1% over the next 12 months.
Consensus
Buy4.13 / 5.00
Avg. Target
US$644.36
+20.1% Upside
Current Price
US$536.40
Last close
Analyst Breakdown (15 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on UTHR's historical volatility
30-Day Vol
47.6%
Annualized
90-Day Vol
32.4%
Annualized
Trend (90d)
-8.3%
Annualized drift
90d Mean
US$520.80
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$531.15 | US$450.73 – US$625.91 |
| 60 trading days | US$525.95 | US$416.98 – US$663.39 |
| 90 trading days | US$520.80 | US$391.91 – US$692.08 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Financials
- Revenue (TTM)
- $3.15B
- EBITDA
- $1.50B
- Profit Margin
- 41.56%
- ROE (TTM)
- 19.32%
- EPS (Diluted)
- 27.92
- Book Value
- 149.97
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About UTHR.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| GUTS | Fractyl Health, Inc. Common Stock | $4.56 | +1020.39% |
| CMND | Clearmind Medicine Inc. Common Shares | $6.00 | +739.16% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.24 | +74.48% |
| VEEA | Veea Inc. | $5.72 | +71.77% |
| PDSB | PDS Biotechnology Corp | $1.20 | +60.21% |
| BEAT | Heartbeam Inc | $0.65 | +50.39% |
| RITRF | Reitar Logtech Holdings Limited | $0.01 | +42.86% |
| QTEX | QTREX Quantum Ltd. | $1.54 | +40.00% |
UTHR.US news timeline
4 articles covering UTHR.US, most recent first
Latest